Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 6Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Ovarian Epithelial 5Breast Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Rectal Neoplasms 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms, Plasma Cell 3Multiple Myeloma 3Hodgkin Disease 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Burkitt Lymphoma 3Bile Duct Neoplasms 3Anus Neoplasms 3Waldenstrom Macroglobulinemia 2

Interventions

pembrolizumab 157Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 91Irinotecan 88Carboplatin 86Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 47Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Interleukin-12 Subunit p35 × Clear all
NCT03030378 2026-05-19

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
36 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡